ACN

Outcome

—

Return

—

Status

—

Subscribe to read

Outcome

—

Return

—

Status

—

Subscribe to read

Outcome

–

Return

+0.34%

Status

scored

Initiate ACN at 2-3% portfolio weight with staged scaling to 5% on confirmation, using pullbacks to the 10 EMA zone ($203-205) for add-on entries rather than chasing the $208 breakout; hard stop set at $193.22. The Overweight call is grounded in a 13.1x forward P/E valuation floor against a 26% ROE compounder generating $10.9B FCF with net cash and 3.5% dividend yield, but position capped at 5% until the 2026-10-01 corporate action is publicly identified and MA stack reliability is verified.

Outcome

✗

Return

+5.96%

Status

scored

Maintain ACN at Hold with the structural floor (12.33x forward P/E, 26% ROE, 3.54% yield, $11.18B FCF) capping downside but technicals unresolved—unconfirmed golden cross, MACD at +4.04 vs +8.5 August peak, 82% volume collapse post-gap, stock 30% below December 2025 peak. Do not initiate fresh longs or trim; hard stop at $192, with defined add triggers at confirmed 50/200 golden cross (2+ sessions) or close >$200 on volume >10M.

Outcome

✗

Return

+1.68%

Status

scored

Tactical Underweight: Reduce ACN by 10-12% in two equal tranches at $193-195 over 1-3 sessions with a hard stop at $178 close, while preserving the core position to capture the 3.51% dividend yield and structural floor. Re-engagement triggers include a golden cross, close above $200 on volume >25M with MACD histogram re-expanding above +1.5, or 10Y sustained below 4.0% with Fed dovish pivot. Hard invalidation (full re-add): close >$212 reclaiming the October 1 gap. Hard escalation to Sell: close <$171 or forward EPS cut below $14.50.

Outcome

✗

Return

-0.85%

Status

scored

Initiate Overweight with a 50% starter position (~2% of portfolio) at $194-196, reserving staged adds for $178-182 on 50-DMA pullback and $212-215 on confirmed close above >25M volume. Hard stop at $173 close-based. The 12x forward P/E on 26% ROE with $16B FCF, $5B+ net cash, and 10.3% shareholder yield is compelling, but the confirmed death cross and $25.3B goodwill exposure (79% of book value) warrant staged execution over full conviction.

Outcome

✓

Return

-1.94%

Status

scored

Analysts unanimously recommend Hold for ACN at benchmark weight, neither adding at $198-200 nor trimming, as the technical setup remains unresolved following the Oct 2 reversal (-6.3% intraday) and rolling 200 SMA. The structural floor (13.6x forward earnings, 26% ROE, 17% FCF margin, net cash, $8.3B shareholder return) is deemed too solid to justify reduction, while post-climactic reversal lessons argue against aggressive additions. Two-sided triggers define the reaction framework: bullish add at close >$204 with RSI >60 on rising volume, bearish trim at close <$193 with RSI <50, and hard stop at $178 close-based.

Outcome

✗

Return

-6.31%

Status

scored

Analysts unanimously maintain HOLD on ACN at $212, avoiding chasing the +15.8% single-session move (a 99th-percentile event). The recommended action is a disciplined tiered buy approach: $200-205 (1/3), $193-195 (1/3), and $185-190 optional (1/3), each with 2% sizing, capped at 4-6% total exposure. A hard stop at $185 close-based governs risk, with mandatory reassessment at the Fed meeting Oct 29 and Q1 FY27 print mid-late December.

Outcome

✗

Return

+15.78%

Status

scored

Disciplined 15-20% trim across two tranches reduces ACN exposure to ~60-70% benchmark weight, addressing simultaneous technical breakdown, hawkish macro headwinds, and proximity to Oct 1 binary catalyst while preserving structural floor carry and mean-reversion optionality; aggressive full-exit and put-hedge proposals rejected as they sell cheap optionality into elevated implied vol.

Outcome

✗

Return

+3.53%

Status

scored

Trim ACN by 15-20% in two tranches to address binary catalyst risk on Oct 1 while preserving 80-85% residual for the structural floor. Tranche 1 (10-12%) executed at $175-180 immediately; Tranche 2 (5-8%) only triggered if Oct 1 confirms bearish thesis via guide-down, soft bookings, or close below $171 lower Bollinger. Hard stop at $195 close-based (200 SMA), with re-evaluation mandatory at Oct 1 and +30 days post-earnings.

Outcome

✓

Return

+1.52%

Status

scored

Maintain Hold with a tactical 10% trim to reduce binary-catalyst exposure ahead of the Oct 14 Analyst Day while preserving the structural floor. Stop tightened from $163 to $170 close-based (0.96x ATR) to force re-evaluation before testing major breakdown support. Two explicit re-engagement paths defined: BULL (close >$181 on volume >7M shares with positive MACD histogram + GenAI bookings disclosure → add to neutral weight with stop at $174) and BEAR (in-line print with cautious AI commentary + close below $170 → exit fully, reassess at $154–$163).

Outcome

–

Return

-0.93%

Status

scored

Execute a ~30% trim from current ACN weight immediately (1–2 sessions) at $176 to harvest asymmetric downside while preserving structural-floor participation; a $169 close-based stop (vs. the rejected $173.50) allows normal volatility absorption without whipsaw risk, with mandatory reassessment at Q1 FY27 earnings (late Sep/early Oct 2026). Re-engagement triggers include Path A ($182+ reclaim with volume >7M shares, positive MACD histogram, RSI >50), Path B ($170 pullback with bullish MACD divergence), and full exit on $169 stop trigger.

Outcome

✓

Return

-0.73%

Status

scored

Execute a tactical 10–15% trim from current weight immediately, reducing exposure to mitigate alpha bleed while preserving the structural floor thesis in the residual position. Reject the proposed Overweight/Buy as replicating the 9/8 error pattern, tighten hard stop to $170 close-based, and mandate reassessment at Q4 FY26 earnings (early December 2026).

Outcome

✗

Return

-3.33%

Status

scored

Maintain HOLD on ACN with approximately flat expected return and slight positive risk-adjusted profile; add only on close above $197 with >7M shares volume AND Q4 FY26 GenAI bookings acceleration, trim 10-20% on close below $172.91 with elevated volume, with hard stop at $170. The rating reflects binding lessons from prior failed calls: 12.5x forward P/E with 24.4% ROE and 3.55% yield creates too thick a structural floor to justify Underweight, while 50-60% bull case probability is overstated at 25-35%, making Buy/Overweight premature. Mandatory reassessment at Q4 FY26 earnings in mid-to-late October.

Outcome

✓

Return

-0.11%

Status

scored

Three analysts converge on Hold amid a $172-$197 trading range near its midpoint where directional conviction is unwarranted. Structural floor metrics (14.66x P/E, 10.8% FCF yield, $3.3B net cash, 24.4% ROE) have held through multiple Underweight tests, while bearish technical signals (price below 3 of 4 MAs, negative MACD) and goodwill risk ($25.3B, 37% of assets) are real but bounded. Q4 FY26 earnings serve as the binding reassessment catalyst.

Outcome

✓

Return

-1.28%

Status

scored

Trim 20-25% of ACN position at current $186-190 weakness over 1-2 trading sessions, moving to ~70-75% benchmark weight. The $175 Morgan Stanley price target sits below current spot, technicals show damage (MACD bearish cross, failed $195-197 resistance twice), and 12.7x forward P/E with 5-7% organic growth implies stretched 1.8-2.5x PEG. Full Sell rejected due to structural floor (24% ROE, $12.1B TTM FCF, $1.78B net cash, 3.6% dividend yield, defended 50 SMA at $165).

Outcome

✗

Return

+2.66%

Status

scored

Trim ACN to 40-50% of benchmark weight immediately via weakness-based execution (sell into current weakness, not resistance, within 1-2 sessions). Defend the residual with a hard stop at $170.99 (50 SMA), preserving exposure to the structural floor (12.35x forward P/E, 17% EPS growth, $12.1B FCF, net cash, 3.43% dividend) while avoiding the 9/17 failure mode of waiting for a relief rally that the bear case argues is unlikely to materialize. Reassess to Hold on October 2026 earnings beat-and-raise or break above 200 SMA ($197) with volume and positive MACD histogram; upgrade to Sell on bookings confirmation, goodwill impairment, or close below $170.99.

Outcome

✓

Return

-4.73%

Status

scored

Maintain ACN at 50% benchmark weight as an Underweight position (not passive Hold), with execution discipline around the defined trim trigger at $195-198 resistance and hard stop at $176 close. The Underweight rating reflects damaged intermediate-term momentum and hostile macro, while the structural floor (24% ROE, $12B TTM FCF, 6%+ capital return yield) prevents a full Sell; mandatory reassessment at Q4 FY26 earnings print.

Outcome

✓

Return

+0.34%

Status

scored

Maintain reduced ACN position at 3-3.5% portfolio weight with a $175 hard stop; add on pullback to $178-183 with constructive momentum or a close above $200 with volume exceeding 40M, and trim on failed breakout at $195-198 with weakening momentum or breakdown below $175 on rising volume. Mandatory reassessment at Q4 FY26 earnings (Sept-Nov 2026).

Outcome

✓

Return

-1.94%

Status

scored

Tactical trim of 40-50% of ACN weight over 3-5 trading sessions, capping residual at 50% benchmark weight, with hard stop at $186 close (10 EMA). The 9/14 reflection explicitly requires a tactical trim rather than passive Hold for this exact setup (third 200 SMA rejection at $198.29, MACD bearish cross, Hold underperformance), while the structural floor ($11.5B cash, 10.2% FCF yield, 50 SMA at $168) prevents a full Sell. Re-engagement requires either pullback to $168-175 zone with momentum stabilization or breakout above $198.29 on volume >40M with macro improvement.

Outcome

✓

Return

-0.82%

Status

scored

Maintain ACN at 1.5-2% portfolio allocation (Hold) as the thick structural floor—$25B+ cash, $12B FCF, 24% ROE, defended 50 SMA at $165—outweighs the 200 SMA rejection and MACD bearish cross at -1.01; hard stop at $175 close with structured adds at $170-165 pullback or $199 breakout with volume confirmation, respecting binding prior lessons that trimming into technical rejections in this setup has bled alpha.

Outcome

✗

Return

+6.04%

Status

scored

ACN remains a Hold at ~$184 with 1-2% portfolio allocation, supported by a structurally sound cash flow floor (11.7% FCF yield, $25B+ cash, 3.66% dividend) but constrained by damaged intermediate-term momentum (MACD at -1.94, price below $185.51 VWAP) and a binary Q4 FY26 catalyst risk. The disciplined expression is neutral weight with defined add triggers at $170-165 flush or $195 breakout, hard stop at $165 close, and mandatory reassessment at Q4 FY26 earnings with a 5-day time-stop on unfired triggers.

Outcome

✗

Return

+3.37%

Status

scored

Maintain ACN at Hold with rating confirmed as HOLD, carrying the position for its structural floor (11.1% FCF yield, 12x forward P/E, $1.78B net cash, 3.7% dividend, $4.7B annualized buyback, 14.8% total cash return) rather than adding aggressively given a fresh bearish MACD crossover (histogram at -2.23), price 10.6% below a still-declining 200 SMA at $199, a binary Q4 FY26 catalyst within ~3 weeks, and hostile macro (10-year approaching 5%, 93% Polymarket no-Fed-cut pricing).

Outcome

✗

Return

+1.20%

Status

scored

Trim ACN to ~50% of normal single-name sizing under Underweight rating; prior 2026-09-08 Overweight (-1.8%/-1.3% alpha) is binding and prohibits fresh capital initiation at spot. Pre-commit scale-in triggers only at $155-160 with momentum stabilization: Tranche 1 (30%) requires close below $160 with MACD histogram turning positive and RSI >35; Tranche 2 (30%) requires daily close above $175.80 with expanding MACD and volume >5M; Final tranche (40%) reserved for post-Q3 FY26 earnings reaction. Hard stop on residual at $162.48 close; mandatory reassessment at earnings (~3 weeks) and 30-day post-earnings.

Outcome

✗

Return

-1.80%

Status

scored

Analysts converge on a constructive ACN outlook given the compelling 12.2x forward P/E valuation floor, 24% ROE, ~$12B FCF, and Google Cloud partnership optionality, but recommend staged execution with 35-40% initial tranche at $179 to honor the damaged short-term technicals (fresh MACD bearish crossover, close below 10 EMA/VWMA) and binary earnings catalyst within three weeks. Full position capped at 1.0x normal single-name sizing with hard add rules: 25% only on confirmed close above $185 with rising volume and MACD re-flip positive, final 25% reserved for post-earnings confirmation of forward EPS integrity and AI-deployment revenue disclosure.

Outcome

✗

Return

-4.12%

Status

scored

Analysts recommend maintaining Accenture at current weight given a valuation floor (12.74x forward P/E, 10.6% FCF yield, $1.78B net cash, 3.38% dividend) that rules out a Sell, but fresh MACD bearish cross, triple resistance at $192/$195/$199.95, and hawkish macro (93% no-Fed-cut) argue against adding at current levels; wait for the tape to clarify before increasing exposure.

Outcome

✗

Return

-3.31%

Status

scored

Maintain Accenture at current sizing capped at 4–5% of the portfolio without adding around $193, as Q3 FY26 record revenue of $18.72B, 16.96% margin, $12B FCF, and 3.47% dividend yield support the core, while declining volume, RSI near 68, and the declining 200-day SMA near $200.20 prevent upgrading to Overweight. The investment thesis balances fundamental earnings support against decelerating growth, goodwill/intangible risks of ~$27.8B, and the unresolved late-September Q4 FY26 guidance catalyst. Enforce $175 as the hard risk line; move to Overweight only after a weekly close above ~$205 with volume above 6M shares and renewed MACD strength.

Outcome

✗

Return

+2.90%

Status

scored

Maintain ACN HOLD at ~$188 with a price target of $201 (3-6 months); do not add at spot given the fresh MACD bearish crossover (histogram -0.19), price 6.5% below a declining 200 SMA, and binary September FY26 earnings 3-4 weeks away. Preserve 10-15% measured add capacity for the $180-184 pullback zone (20 SMA) with MACD histogram turning up, or alternatively a close above $192.26 on volume >5M with histogram re-expanding—each sized at 25% of intended exposure—while collecting the 3.47% dividend and relying on the structural floor (24% ROE, $12B FCF, $1.78B net cash, 8.6% total capital return yield) to defend the position.

Outcome

✓

Return

-0.22%

Status

scored

Maintain Hold on ACN at ~$188 with a widened stop to $178 close (1.5 ATR) and two achievable add tranches at 25% each: pullback to $180-184 zone or daily close above $192.26 on volume >5M with MACD histogram re-expanding. The MACD bearish divergence and 200 SMA resistance overhead (~201) argue against spot adds into the September Q4 FY26 binary catalyst, while the structural floor (3.44% dividend yield, $9.6B capital return, net cash position) supports maintaining core exposure. Add an explicit trim-50% rule if price closes below $155 on/around the September earnings print.

Outcome

✓

Return

-0.88%

Status

scored

Hold ACN at $189.76 with three refinements: replace the sub-ATR stop at $183.45 with a $178 close (1.5x ATR), replace the restrictive five-condition "200 SMA + 30M volume" trigger with two achievable entry paths (pullback to $178-183 zone OR breakout above $192.26 with MACD histogram re-expanding), and add a 50% trim rule if price closes below the 50 SMA at $155 around the September Q4 FY26 earnings print. The September binary catalyst (~3 weeks away) and MACD histogram divergence warn against fresh capital deployment at spot, supporting Hold-to-modest-Overweight rather than a full starter position.

Outcome

✓

Return

+0.08%

Status

scored

Overweight ACN with 25-35 bps starter position at current $185-190 levels (~$187.50), capping total exposure at 50-75 bps through the late-September Q4 FY26 binary catalyst, with potential to scale to 100-150 bps post-earnings on clean print with bookings inflection >5% YoY, operating margin ≥16.5%, and close above 200 SMA ($201.46). The floor metrics—12.94x forward P/E on 24.4% ROE, $12B FCF with 142% conversion, $1.78B net cash, and 3.48% dividend yield—have repeatedly absorbed bearish calls, and the technical setup has shifted constructive with fresh MACD cross and rising 10 EMA, warranting measured engagement rather than waiting.

Outcome

✓

Return

+1.19%

Status

scored

ACN maintains a HOLD rating with active execution discipline despite convergence from all three analysts. The structural floor is genuinely hard (12.8x forward P/E on 24% ROE, $12B FCF, 3.6% yield, $10B+ capital return), preventing Underweight, but the probability-weighted math ($186.50 vs. $187 spot) and unresolved binary catalysts (Jackson Hole Friday, Q4 FY26 earnings late September, 200 SMA reclaim at $201) preclude Buy. The framework commits to maintaining position size, collecting the 3.6% dividend carry, and adding only on specific triggers: $168-172 post-dovish Jackson Hole, or confirmed close above $201.46 with volume and follow-through, with $172 hard stop and $195-200 partial trim zone.

Outcome

✗

Return

+3.31%

Status

scored

Hold at $181.38 maintains the structural floor (12.4x forward P/E, 24.4% ROE, $1.78B net cash, 3.49% yield) against Underweight, while the death-cross regime, MACD bearish re-cross setup, and 87% Polymarket no-cut pricing prevent Overweight. Staged entries at $176.50 and $170-$172 with hard stop below $170 operationalize the fundamental case without conviction-overload ahead of binary Q1 FY26 earnings catalyst in late September.

Outcome

✗

Return

-2.97%

Status

scored

Overweight rating maintained but immediate initiation at $186.93 is rejected in favor of staged entry starting at $180–181; the 30% first tranche should await the plan-defined zone rather than chase into overhead resistance at $202 and a binary Q3 FY26 earnings catalyst. Total position capped at 2–2.5% NAV with a hard stop at $170 and a $160 weekly close trigger to sell half the position.

Outcome

✓

Return

+0.21%

Status

scored

Maintain ACN core position with Hold rating, as the stock sits near upper Bollinger resistance at $188.59 after a 26.7% one-month rally, making aggressive adds at $186 premature; trim modestly into $188-190 if overweight (>5%) to lock in gains. Set hard stop at $165 and do not deploy new capital until either a confirmed breakout above $188.59 or a pullback to the $170-175 re-entry zone with volume confirmation.

Outcome

–

Return

+0.67%

Status

scored

Trim ACN by 40–50% into the $188–$190 Bollinger upper band resistance zone while maintaining a residual core position, as the 7.2% total shareholder yield provides a structural floor against a full exit. The Underweight rating is supported by bearish MACD divergence, declining 200 SMA at $202.54, and a 12.6x forward P/E de-rating from 18–28x, though the 10.7% FCF yield and net cash position justify retaining a core exposure. Hard stop is $170 on residual with mandatory reassessment at Q4 FY26 earnings.

Outcome

✓

Return

+2.17%

Status

scored

Maintain ACN at $181.35 with HOLD rating as all three risk analysts plus research manager and trader converge on the same call; the valuation floor (12.4x forward P/E, 10.9% FCF yield, $9.6B TTM capital return) prevents Underweight while the unresolved technical setup (MACD bearish divergence, declining 200 SMA at $203 overhead, death cross) prevents Buy/Overweight. Tranche-based tactical adds are permitted at $171-176 on constructive pullback or on confirmed breakout above $203 with volume >6M, with partial trim discipline at $195-200 on momentum divergence and mandatory reassessment at Q4 FY26 earnings (late September) where bookings inflection >5% YoY upgrades and forward EPS cut >5% downgrades.

Outcome

✓

Return

-0.99%

Status

scored

Maintain ACN at $183 without adding fresh capital; neither conviction-overload Buy at elevated levels nor passive Hold that leaks alpha is warranted. Scale into $152-$169 with volume confirmation at 50 SMA for 5-7% portfolio sizing; trim at $200+ without confirmed close above 200 SMA ($203); hard stop at $118 with mandatory Q4 FY26 earnings reassessment watching GenAI bookings, book-to-bill ratio, and operating margin trajectory (below 16.5% signals cost-cut cycle exhaustion).

Outcome

✗

Return

+5.92%

Status

scored

Trim 40-50% of ACN exposure to half benchmark weight with stop at $180-182, supported by three-analyst bearish consensus on declining 200 SMA ($203.46), MACD histogram flipping negative, institutional exits citing AI displacement, unresolved June 18 anomaly, and 320 bps Q2 FY26 margin compression to 13.8%. Allocate 0.5-1% to SPX/QQQ puts for tail-risk hedge; mandatory reassessment at Q4 FY26 earnings (late September).

Outcome

✓

Return

+1.74%

Status

scored

Initiate ACN at $169-170 with a modified 3-tranche scale-in strategy, reducing Tranche 1 from the trader's 35% to 25% of target size (≈1.6% portfolio risk). Hard stop at $137 on full position; Tranche 1 trailing stop at $155 until Tranche 2 deploys. The decision balances the compelling valuation (11.6x forward P/E, 11.6% FCF yield, 24.4% ROE) against prior failed decision patterns (Aug 12 Buy: -1.6% alpha, Aug 14 Hold: -3.4% alpha), choosing disciplined partial exposure over full conviction or inaction.

Outcome

✗

Return

-3.91%

Status

scored

Five-way convergence (research manager, trader, conservative analyst, neutral analyst, and prior-pattern evidence) all point to Hold on ACN, with only the aggressive analyst advocating scale-in. The $150 hard floor stop remains in place while the 12x forward P/E with 3.63% dividend yield provides floor defense against Underweight, but the descending 200-SMA at $204 overhead and unresolved bookings debate until Q4 FY26 earnings (late September) prevent Buy/Overweight. Upgrade trigger is confirmed close above $204 on volume ≥8M shares; downgrade trigger is close below $150 on volume.

Outcome

✓

Return

-0.90%

Status

scored

All five analysts independently converge on Hold given the genuine structural tension between a hard valuation floor (12.16x forward P/E, 3.63% dividend yield, $1.78B net cash) and unresolved technical/fundamental risks (200 SMA 12.7% overhead, 5-quarter revenue range-lock, June 18 gap-down unexplained). Prior ACN decisions establish that aggressive directional calls consistently underperform simple Hold, while the position preserves the $6.50/share annual dividend carry and FCF optionality without committing fresh capital into overhead supply at $204.54.

Outcome

✗

Return

-0.92%

Status

scored

Initiate ACN with a Buy rating and phased deployment strategy, entering 40-50% at $180 and scaling to full weight on a pullback to $170-172. Set a hard stop at $158, with primary target of $205 and realistic secondary target of $215-235 over 12-18 months on a 15-16x multiple re-rating. Hedge using a $170/$150 December put spread, trim 25% at $195 and another 25% at $215, and cap position at 50% of full weight into late September FY26 Q4 earnings.

Outcome

✓

Return

+0.18%

Status

scored

Maintain ACN at current levels (~$188) without adding into the 200 SMA resistance at $205 (RSI 70, +54% rally) or trimming aggressively given the hard valuation floor (12.25x forward P/E, 24.4% ROE, $12.6B FCF, net-cash). Set price alerts at $205 for breakout upgrade and $152 for downgrade, with Q4 FY26 bookings as the decisive catalyst. For overweight accounts, the collar (buy $155-160 puts, sell $230+ calls) monetizes elevated IV while defining downside risk.

Outcome

✗

Return

+0.88%

Status

scored

Trim ACN by 15-20% in staged tranches (10% now at $178, additional 5-10% on push to $186) while retaining an 80-85% core position for its 3.7% dividend yield and re-engagement optionality. Set trailing stop at 10 EMA (~$168) with full exit on daily close below $155; do not add below $165. Re-engagement triggers include partial add at $140-152 stabilization or full add on confirmed $205 reclaim with >5M volume holding 5+ sessions, with FY2026 earnings (Sept/Oct) as the decisive catalyst.

Outcome

✓

Return

+1.44%

Status

scored

Initiate an Overweight position in ACN via a staged approach: Tranche 1 (30% of target weight, 2.5% book cap) at current levels around $175.72, with a $156 hard stop for gap-risk protection. Tranche 2 deploys on 50 SMA retest hold or Bollinger upper band close above $183, while Tranche 3 requires 200 SMA reclaim at $205.84 on ≥7M volume. An explicit September earnings checkpoint mandates halving all tranches and re-evaluation upon any material bookings disappointment.